ClinConnect ClinConnect Logo
Search / Trial NCT06895525

Efficacy of HellenCare in Early-Stage Alzheimer's Disease

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Mar 19, 2025

Trial Information

Current as of April 29, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a supplement called HellenCare to see if it can help improve memory and daily functioning in people with early-stage Alzheimer's disease, a type of dementia that affects thinking and memory. The researchers will compare the results of those taking HellenCare with a group receiving a placebo, which is a dummy treatment that doesn’t contain the active ingredient. The goal is to find out if HellenCare is effective and safe for those with this condition.

To participate in the trial, individuals need to be between 50 and 85 years old and have recently been diagnosed with Alzheimer’s disease or mild cognitive impairment related to Alzheimer's. They should also have a certain level of cognitive function, as measured by a memory test. Participants must be willing to attend scheduled visits and follow the study's guidelines. It's important to note that people with other types of dementia, severe neurological issues, or certain mental health conditions won't be eligible for the study. If you or someone you know might be interested in participating, keep an eye out for updates on when the trial will start recruiting participants.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants aged 50 to 85 years
  • Clinically diagnosed for the first time with probable Alzheimer's disease dementia (AD dementia) or AD-related mild cognitive impairment (MCI) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical criteria.
  • MMSE (Mini-Mental State Examination): Score between 22 and 30.
  • CDR (Clinical Dementia Rating): Total score of 0.5 or 1. Memory domain score on CDR: ≥0.5.
  • Able to comply with study procedures and attend scheduled visits.
  • Willingness to participate and provide informed consent.
  • Exclusion Criteria:
  • Presence of other dementia-causing conditions (e.g., vascular dementia, Lewy body dementia, etc)
  • Severe neurological comorbidities (e.g., history of seizures, cerebral infarction, intracerebral hemorrhage, traumatic brain injury, brain tumors, etc.)
  • Presence of severe anxiety, depression, schizophrenia, bipolar disorder, or other psychotic disorders requiring active treatment.
  • History of alcohol or drug dependence within the past 1 year.
  • Allergies to study dietary supplement.
  • Use of anti-dementia medications ( e.g., donepezil, galantamine, memantine, etc).

About Peking University First Hospital

Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported